Novel compounds and pharmaceutical compositions useful as EGFR tyrosine kinase inhibitors. Methods of the invention include administration of the EGFR TK inhibitors to treat diseases characterized by enhanced expression of EGF, including cancers, particularly breast cancer. Additionally, a homology model representing the structure of EGFR kinase domain is provided, which model is useful for the rationally design and screening of compounds predicted to bind favorably to EGFR and to inhibit EGFR TK.
作为
表皮生长因子受体
酪氨酸激酶
抑制剂的新型化合物和药物组合物。本发明的方法包括使用
表皮生长因子受体 TK
抑制剂治疗以
表皮生长因子受体表达增强为特征的疾病,包括癌症,尤其是乳腺癌。此外,本发明还提供了代表
表皮生长因子受体激酶结构域的同源模型,该模型有助于合理设计和筛选预测能与
表皮生长因子受体结合并抑制
表皮生长因子受体TK的化合物。